{
  "docId": "019de073-7cac-75f7-8c4d-c1df42c29745",
  "docSlug": "674201d8cef93b1820f78aa5772cd90f",
  "documentTitle": "ATAI | Investor Presentation Deck | 36 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 36,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 15,
  "notes": "The slide uses a line chart to demonstrate clinical efficacy over 12 weeks compared to baseline.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-7cac-75f7-8c4d-c1df42c29745/12",
  "deckHref": "/decks/019de073-7cac-75f7-8c4d-c1df42c29745",
  "deckJsonHref": "/decks/019de073-7cac-75f7-8c4d-c1df42c29745.json",
  "deckAnchorHref": "/decks/019de073-7cac-75f7-8c4d-c1df42c29745#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.58,
        "x": 0.37,
        "y": 0.32
      },
      "kind": "chart",
      "text": "COMP360 Phase 2b trial results showing change from baseline in MADRS score over 12 weeks.",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2569a8fe-0cfe-4098-b0e8-5947daccd677",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.28,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "list",
      "text": "OWNERSHIP: 22.5% | PRODUCT: Oral Psilocybin (COMP360) | PHARMACOLOGY: 5-HT2A-R agonist | PRODUCT FEATURES: Rapid onset, potential for sustained efficacy | INDICATIONS: TRD, Anorexia | STATUS: Phase 3 (TRD) | IP: Proprietary formulation",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "53265e4e-d952-4f90-8fc9-833d6805141a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.58,
        "x": 0.37,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Source: Schedule 13D filed with the SEC as of November 29th, 2021. Note: MADRS = Montgomery-Åsberg Depression Rating Scale.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a3c43edf-fe7f-4696-96ef-c1355da98e04",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.58,
        "x": 0.37,
        "y": 0.08
      },
      "kind": "title",
      "text": "COMP360 Phase 2b trial showed a rapid, sustained reduction in depressive symptoms",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f6d96cb9-33e1-4cb9-bd43-9a90a54a5846",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.15,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "SUMMARY",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "462879aa-b2dd-4738-9c36-9298883e5839",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "data-story-arc",
      "slug": null,
      "matchId": "1e2c9108-901d-440e-ba43-ccbc22427a3c",
      "evidence": "Presents clinical data to support a specific therapeutic claim.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 12,
      "from": 11,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "cd74ca1e-8ed1-4265-85bb-afa949f8e04d",
      "evidence": "Slides 11-12 present the problem and traction for depression treatment",
      "position": 0,
      "objective": "Highlight the need for innovation in depression treatment",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}